Search clinical trials for: linagliptin placebo

Total 53971 results

University of Oslo School of Pharmacy
Oslo University Hospital

Completed

Sitagliptin in Renal Transplant Recipients

Glucose Intolerance

Norway
Kowa Research Institute, Inc.

Completed

A Study Comparing the Safety, Tolerance, and Efficacy of Various Doses of SK-0403 Versus Placebo and Sitagliptin 100 mg in Patients Not Well-Controlled on Metformin Therapy

Type 2 Diabetes

United States
Hannover Medical School

Unknown

Vascular Effects of Sitagliptin in Diabetes Mellitus

Type 2 Diabetes Mellitus

Germany
Phenomix
Forest Laboratories

Terminated

Study to Evaluate Safety and Efficacy of Dutogliptin in Type 2 Diabetes Mellitus Subjects With Moderate and Severe Renal Impairment

Type 2 Diabetes Mellitus | Renal Impairment

United States, Russian Federation, Ukraine
Fayoum University
Boehringer Ingelheim

Completed

Contrast Nephropathy in Type 2 Diabetes (VCG4)

Diabetes | Microalbuminuria | Kidney Function Affection Upon Exposure to Radiocontrast

Egypt
Korea University Anam Hospital

Completed

The Pharmacokinetics, Safety and Tolerability of IN-C009 in Healthy Subjects

Diabetes Mellitus

Korea, Republic of
Albert Einstein College of Medicine

Completed

Sitagliptin Dose Determination Study

Diabetes Mellitus, Type 1

United States
Merck Sharp & Dohme LLC

Completed

Study of Sitagliptin in Older Type 2 Diabetics (0431-047)(COMPLETED)

Type 2 Diabetes
CymaBay Therapeutics, Inc.

Completed

Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of MBX-2982 Administered Daily for 4 Weeks as Monotherapy in Patients With Type 2 Diabetes

Diabetes

United States, Georgia, India
Academisch Medisch Centrum - Universiteit van Amsterdam...
Merck Sharp & Dohme LLC

Completed

Dipeptidyl Peptidase-4 Inhibitors and Alpha-cell Recovery (DARE)

Hypoglycemia | Type 1 Diabetes

Netherlands
Novartis Pharmaceuticals

Completed

A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)

Type 2 Diabetes Mellitus

Canada, United States, Italy, Poland, Puerto Rico
Ono Pharmaceutical Co. Ltd

Completed

Controlled Study of MK-0431/ONO-5435 in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Japan
Washington University School of Medicine
Merck Sharp & Dohme LLC

Completed

Efficacy Study of Sitagliptin to Prevent New-onset Diabetes After Kidney Transplant

Posttransplant Diabetes Mellitus

United States
University at Buffalo
Merck Sharp & Dohme LLC

Completed

The Effect of Januvia (Sitagliptin) on Oxidative Stress in Obese Type 2 Diabetic Subjects (1928)

Type 2 Diabetes

United States
Merck Sharp & Dohme LLC
Duke Clinical Research Institute, Oxford Diabetes Trials Unit

Completed

Sitagliptin Cardiovascular Outcomes Study (MK-0431-082) (TECOS)

Type 2 Diabetes Mellitus
Eli Lilly and Company

Terminated

A Study of LY2409021 in Participants With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

United States, Puerto Rico, Greece, Taiwan
Lund University
Merck Sharp & Dohme LLC

Completed

Sitagliptin and Glucagon Counterregulation (SITACLAMP)

Type 2 Diabetes

Sweden
Novo Nordisk A/S

Completed

Efficacy and Safety of Switching From Sitagliptin to Liraglutide in Subjects With Type 2 Diabetes Not Achieving Adequate Glycaemic Control on Sitagliptin and Metformin (LIRA-SWITCH™)

Diabetes Mellitus, Type 2 | Diabetes

United States, Israel, Canada, Hungary, India, Spain, Puerto Rico
University Hospital, Gentofte, Copenhagen

Completed

Correlation Between Plasma- and Endothelial DPP-4 Activity

Type 2 Diabetes Mellitus

Denmark
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety and Efficacy of Sitagliptin 100 mg in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control (MK-0431-229)

Type 2 Diabetes Mellitus
Rabin Medical Center

Terminated

Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19

Glucose Metabolism Disorders | Respiratory Tract Diseases | Diabetes Mellitus, Type 2 | Diabetes Mellitus | Endocrine System Diseases | COVID 19 | Coronavirus | Metabolic Disease | Severe Acute Respiratory Syndrome Coronavirus 2 | Sars-CoV2 | Hormones | Hypoglycemic Agents | Incretins | Dipeptidyl-Peptidase IV Inhibitors and other conditions

Israel
Merck Sharp & Dohme LLC

Completed

Sitagliptin Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus (T2DM)
Boehringer Ingelheim
Eli Lilly and Company

Completed

Bioequivalence of a FDC Tablet of Linagliptin/Metformin (2.5mg/1000mg) Extended Release in Healthy Subjects.

Healthy

Germany
Ministry of Public Health, Argentina
Aix Marseille Université; Instituto de Biología y Medicina Experimental, IBYME...

Unknown

Effect of Linagliptin on TRL Metabolism

Type 2 Diabetes

Argentina
Boehringer Ingelheim

Completed

Bioequivalence of a 2.5 mg Linagliptin / 500 mg Metformin Fixed Dose Combination Tablet Compared With Single Linagliptin 2.5 mg and Metformin 500 mg Tablets Administered Together in Healthy Volunteers

Healthy
Eli Lilly and Company

Terminated

A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM) (IMPERIUM)

Diabetes Mellitus, Type 2

United States, Puerto Rico, Germany, United Kingdom, Austria
University of Pennsylvania

Recruiting

Effects of Sitagliptin in Individuals With Genetically Decreased DPP4

Heart Failure | Type2 Diabetes | Genetics Disease

United States
Li Bo

Completed

Effect of Sitagliptin on Progression of Coronary Intermediate Lesion

Type 2 Diabetes Mellitus | Atherosclerosis

China
GlaxoSmithKline

Completed

A Study in Type 2 Diabetic Subjects on Stable Metformin Therapy to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Co-administering Single and Multiple Oral Doses of GSK1292263

Diabetes Mellitus, Type 2

United States
University of Alabama at Birmingham

Terminated

Changes in Bone Turnover With Increased Incretin Hormone Exposure (DRTC)

Type 2 Diabetes Mellitus

United States
Merck Sharp & Dohme LLC

Completed

Sitagliptin Mechanism of Action Study in Patients With Type 2 Diabetes Mellitus (0431-059)

Type 2 Diabetes Mellitus (T2DM)
Merck Sharp & Dohme LLC

Completed

Sitagliptin Dose Comparison Study in Patients With Type 2 Diabetes (MK-0431-077)(COMPLETED)

Type 2 Diabetes
Takeda

Terminated

Comparison of Fasiglifam (TAK-875) to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes

Glycemic Control

United States, Bulgaria, Malaysia, Korea, Republic of, Australia, Czech Republic, Hungary, Thailand, Italy, Slovakia, Croatia
Merck Sharp & Dohme LLC

Completed

MK0431 Monotherapy Study in Patients With Type 2 Diabetes Mellitus (0431-040)

Type 2 Diabetes Mellitus
University Hospital, Gentofte, Copenhagen
Merck Sharp & Dohme LLC

Completed

Long Term Effects of DPP-IV Inhibitor Treatment in Patients With Type 2 Diabetes

Type 2 Diabetes

Denmark
Instituto Nacional de Ciencias Medicas y Nutricion...
Merck Sharp & Dohme LLC

Completed

Treatment With Sitagliptin for Reactive Hypoglycemia Secondary to Dysinsulinism

Reactive Hypoglycemia

Mexico
Boehringer Ingelheim

Completed

Bioequivalence of a Linagliptin / Metformin Fixed-dose Combination (FDC) Tablet Compared With Single Linagliptin and Metformin Tablets Administered Together in Healthy Volunteers

Healthy
Boehringer Ingelheim

Completed

Bioequivalence of a 2.5 mg Linagliptin / 850 mg Metformin Fixed Dose Combination Tablet Compared With Single Linagliptin 2.5 mg and Metformin 850 mg Tablets in Healthy Volunteers

Healthy
Boehringer Ingelheim

Completed

Bioequivalence of Metformin Under Fed Conditions After Administration of Linagliptin / Metformin Fixed Dose Combination Tablet and Single Tablets

Healthy

Germany
Merck Sharp & Dohme LLC

Terminated

A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211)

Type 2 Diabetes Mellitus
AstraZeneca
Eli Lilly and Company

Completed

A Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly to Those of Sitagliptin and Pioglitazone,in Subjects With Type 2 Diabetes Treated With Metformin (DURATION - 2)

Type 2 Diabetes Mellitus

United States, Mexico, India
Icahn School of Medicine at Mount Sinai
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Withdrawn

Mechanisms Underlying Predictors of Success From Obesity Surgery

Obesity

United States
Merck Sharp & Dohme LLC

Completed

Metformin Add-on Regimen Comparison Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-0431A-136)

Type 2 Diabetes Mellitus
Michael A. Nauck

Completed

Antidiabetic Effects of Adding a DPP-4 Inhibitor to Pre-Existing Treatment With an Incretin Mimetic in Patients With T2D

Type 2 Diabetes

Germany
Takeda

Completed

Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus

Diabetes Mellitus

United States, Mexico
Universidad de Guanajuato
Hospital Regional de Alta Especialidad del Bajio

Completed

Effect of Linagliptin + Metformin vs Metformin Alone in Patients With Prediabetes (PRELLIM)

Insulin Resistance | Prediabetic State

Mexico
Boehringer Ingelheim

Completed

Pharmacokinetics and Pharmacodynamics Trial With Linagliptin (BI 1356) 5mg in African American Type 2 Diabetic Patients

Diabetes Mellitus, Type 2

United States
Garvan Institute of Medical Research

Completed

Effects of Glutamine on GLP-1 and Insulin Secretion in Man

Type 2 Diabetes

Australia
Johns Hopkins University
Merck Sharp & Dohme LLC

Terminated

Dipeptidyl Peptidase-4 Inhibition on Glucagon-like Peptide-1 (GLP-1)

Glucose Homeostasis

United States
Merck Sharp & Dohme LLC

Completed

A Study to Assess the Pharmacokinetics, Safety and Tolerability of Sitagliptin in Adolescents (0431-081)

Type 2 Diabetes

3

Subscribe